Whitney Mays, NP
Family · Coeburn, VANPI 1790946358
Payments from drug & device makers
Across 119 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$468
- AstraZeneca$291
- Novo Nordisk$200
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$185
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$114
- Amgen$103
- plus $683 from 19 others
What the payments were for
- Food & beverage$2,045100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $468 |
| AstraZeneca | 14 | $291 |
| Novo Nordisk | 15 | $200 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $185 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $114 |
| Amgen | 7 | $103 |
| Novartis | 6 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Boehringer Ingelheim | 3 | $68 |
| Lilly USA, LLC | 3 | $55 |
| Pfizer | 3 | $51 |
| Exact Sciences | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $31 |
| Lundbeck LLC | 1 | $29 |
| Axsome Therapeutics, Inc. | 2 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Gilead | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $23 |
| Scynexis, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Abbott | 1 | $15 |
| Eisai Inc. | 1 | $12 |
How this compares
$2,045 in reported general payments places this provider in the 80th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 130 | $125,364 |
| EliquisApixaban | 123 | $93,175 |
| MounjaroTirzepatide | 72 | $75,629 |
| XifaxanRifaximin | 15 | $47,175 |
| JardianceEmpagliflozin | 62 | $43,786 |
| VraylarCariprazine Hcl | 21 | $30,514 |
| JanuviaSitagliptin Phosphate | 47 | $29,231 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $20,676 |
| JanumetSitagliptin Phos/Metformin Hcl | 42 | $20,493 |
| MyrbetriqMirabegron | 36 | $19,961 |
| TrintellixVortioxetine Hydrobromide | 25 | $18,347 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 557 | $17,768 |
| RybelsusSemaglutide | 17 | $15,858 |
| Spiriva HandihalerTiotropium Bromide | 15 | $14,039 |
| LinzessLinaclotide | 20 | $12,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $200 | $141,222147 claims |
| PfizerEliquis | $51 | $93,175123 claims |
| Lilly USA, LLCMounjaro, Trulicity | $55 | $87,76684 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $114 | $47,17515 claims |
| Boehringer IngelheimJardiance | $68 | $43,78662 claims |
| AbbVieVraylar, Linzess | $468 | $43,37641 claims |
| AstraZenecaFarxiga, Symbicort | $291 | $25,25849 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $19,96136 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $71 | $18,34725 claims |
| Johnson & JohnsonInvokana | $31 | $12,37211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,332 family providers in Virginia.
Other family in Coeburn
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.